Neurological Biomarkers Market
Number of pages: 100 | Report Format: PDF | Published date: December 15, 2022
Historical Years – 2023 | Base Year – 2023 | Forecasted Years – 2023-2032
|
Report Attribute |
Details |
|
Market size value in 2023 |
US$ 8.13 billion |
|
Revenue forecast in 2032 |
US$ 22.37 billion |
|
Growth Rate |
CAGR of 11.9% from 2023 to 2032 |
|
Base year for estimation |
2023 |
|
Forecast period |
2023-2032 |
|
Segments covered |
type, application, end-user, and region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global neurological biomarkers market was valued at US$ 8.13 billion in 2023 and is expected to register a revenue CAGR of 11.9% to reach US$ 22.37 billion by 2032.
Neurological Biomarkers Market Fundamentals
Neurological biomarkers refer to measurable indicators or characteristics that can be objectively observed, measured, and evaluated to provide information about the state or function of the nervous system. These biomarkers can be found in various biological sources, including blood, cerebrospinal fluid, imaging scans, and other physiological measurements. Neurological biomarkers include specific proteins, genetic markers, imaging features, and physiological measurements associated with neurological conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and others. These biomarkers can aid researchers, clinicians, and healthcare professionals in understanding the mechanisms of neurological diseases, developing targeted treatments, and monitoring the effectiveness of interventions.
[34543585]
Neurological Biomarkers Market Dynamics
The prevalence of neurological disorders, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and others, is increasing globally. As the burden of these disorders grows, there is a heightened need for accurate and early diagnostic tools, driving the demand for neurological biomarkers. According to the WHO, the global prevalence of Parkinson's disease has more than doubled in the last 25 years, with over 8.5 million people affected in 2019. Parkinson's disease resulted in 5.8 million disability-adjusted life years in 2019, representing an 81% rise since 2000, and 329,000 fatalities, representing a more than 100% increase since 2000. Technological advancements, including genomics, proteomics, and imaging techniques, have significantly improved the identification and validation of neurological biomarkers. These innovations enhance the sensitivity and specificity of biomarker detection, contributing to market revenue growth. Early diagnosis of neurological disorders is crucial for effective treatment and management. Neurological biomarkers are pivotal in enabling early and accurate diagnosis, prompting healthcare providers and researchers to invest in these tools. The shift towards personalized medicine, where treatments are tailored to individual patient characteristics, has increased the demand for biomarkers predicting treatment responses and disease progression. Neurological biomarkers facilitate the identification of patient subgroups for more targeted therapies. Biomarkers play a key role in drug development by aiding in patient stratification, monitoring treatment responses, and assessing the efficacy and safety of experimental drugs in clinical trials. Government support, grants, and funding for research in neurology and biomarker development contribute significantly to advancements in the field. Increased funding can spur innovation and translate research findings into clinical applications.
However, Neurological disorders often exhibit complex and multifaceted characteristics, making it challenging to identify specific and reliable biomarkers. The heterogeneity of these disorders can complicate the development of universally applicable biomarkers. Standardization of biomarker assays and protocols is essential for ensuring consistent and reliable results across different laboratories and studies. The absence of standardized procedures can lead to variations in biomarker measurements, hindering the reproducibility and comparability of results. The research and development process for identifying, validating, and commercializing neurological biomarkers can be resource-intensive. High development costs may limit the number of biomarkers brought to market and increase the overall cost of diagnostic tools.
Neurological Biomarkers Market Ecosystem
The global neurological biomarkers market is analyzed from four perspectives: type, application, end user, and region.
Neurological Biomarkers Market by Type
[3123123234]
Based on the type, the global neurological biomarkers market is segmented intogenomic, metabolomic, proteomic, imaging, and others.
With a high revenue CAGR of 31.60%, the proteomics segment dominates the global neurological biomarkers market in 2023. Proteomics provides a deep protein profiling of tissue, plasma, serum, and cerebral spinal fluid (CSF) for biomarker discovery, thus playing a pivotal role in segment revenue growth. Additionally, the proteomics quantitative tool is capable of the high throughput quantification of thousands of proteins from minimal sample volumes, thus increasing the demand for proteomic biomarkers. Neurological disorders often involve complex molecular and cellular processes. Proteomics, which involves the comprehensive study of proteins, allows researchers to investigate a wide range of proteins and their modifications, providing a more detailed understanding of the molecular mechanisms underlying neurological conditions. Proteins play crucial roles in the structure and function of cells, tissues, and organs, making them key biomolecules in neurological disorders. Abnormalities in protein expression, structure, or post-translational modifications can serve as valuable indicators of disease pathology. The field of proteomics has benefited from significant technological advancements, particularly in mass spectrometry and other analytical techniques. These technologies enable researchers to analyze complex protein mixtures, detect subtle changes in protein expression, and identify potential biomarkers with high sensitivity and specificity.
Neurological Biomarkers Market by Application
Based on the applications, the global neurological biomarkers market is segmented into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and others.
The Alzheimer’s disease segment accounted for the highest neurological biomarkers market revenue share in 2023. Alzheimer's disease is the most common form of dementia, and it represents a significant public health challenge globally. The rising prevalence of Alzheimer's disease, especially in aging populations, has led to a heightened demand for biomarkers to aid in early diagnosis and disease monitoring. According to the WHO, Alzheimer’s accounts for approximately 60% to 70% of all dementia cases globally, thus propelling the segment's growth. Diagnosis of Alzheimer's disease can be challenging, especially in the early stages when symptoms may be subtle. Biomarkers play a crucial role in improving diagnostic accuracy and facilitating early intervention. The lack of definitive diagnostic tools has increased the importance of biomarkers in Alzheimer's disease research and clinical practice. Early diagnosis of Alzheimer's disease is essential for implementing timely interventions and improving patient outcomes. Biomarkers, particularly those detected through cerebrospinal fluid analysis, neuroimaging, and blood tests, have become key tools in identifying individuals at risk or in the early stages of Alzheimer's disease. The substantial investments in Alzheimer's disease research from the public and private sectors have fueled the discovery and validation of biomarkers. Funding from government agencies, nonprofit organizations, and pharmaceutical companies has supported large-scale research initiatives to identify reliable biomarkers for Alzheimer's disease. For instance, in October 2023, Imeka announced an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate the development of novel biomarkers for Alzheimer's disease and related dementias. The investment will support the use of Imeka neuroimaging biomarkers in a large-scale, longitudinal study of dementia markers and their progression from pre-symptomatic stages to the onset of Alzheimer’s disease and other types of dementia.
Neurological Biomarkers Market by End User
The global neurological biomarkers market is segmented into hospitals & laboratories, independent diagnostic centers, research organizations, and others based on the end users.
The research organizations segment accounted for a significant neurological biomarkersmarket revenue share in 2023. Research organizations are often at the forefront of early-stage discovery and innovation. They conduct fundamental research to identify novel biomarkers associated with neurological disorders, which can eventually lead to new diagnostic tools and therapies. Research organizations adopt state-of-the-art technologies, including genomics, proteomics, and advanced imaging techniques. Using cutting-edge technologies allows identifying and validating biomarkers with higher sensitivity and specificity. Research organizations frequently collaborate with academic institutions, creating a collaborative environment encouraging interdisciplinary research. These collaborations can accelerate biomarker discovery and facilitate the translation of research findings into practical applications. Research organizations are actively involved in drug development initiatives for neurological disorders. Biomarkers play a critical role in drug discovery and development, as they help in patient stratification, monitoring treatment responses, and assessing the efficacy of potential therapeutics. Research organizations often secure grant funding from government agencies, foundations, and industry partners to support biomarker research projects. This financial support enables them to conduct extensive studies and develop new biomarkers.
Neurological Biomarkers Market by Region
Based on region, the global neurological biomarkers market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounts for the largest neurological biomarkers market revenue generation, accounting for around 43.5% of the market revenue share. The increasing prevalence of neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, in North America drives the demand for effective diagnostic tools. Neurological biomarkers play a crucial role in early diagnosis, monitoring disease progression, and informing treatment decisions. According to the Centers for Disease Control and Prevention (CDC), around 6.5 million people are living with Alzheimer’s in the U.S. The aging population in North America is a significant factor contributing to the prevalence of age-related neurological disorders. As the population ages, there is a higher incidence of conditions like Alzheimer’s disease, leading to a growing need for biomarkers for early detection and management. Robust research and development activities in neurology contribute to discovering and validating novel neurological biomarkers. Academic institutions, research organizations, and biotechnology companies in North America actively engage in research to identify biomarkers for various neurological conditions. Government support and funding for neuroscience research initiatives and projects drive innovation in neurological biomarkers. Investment from government agencies and foundations helps accelerate research, development, and commercialization efforts. North America has a well-established healthcare infrastructure with advanced diagnostic facilities, including hospitals and laboratories.
Neurological Biomarkers Market Competitive Landscape
The prominent players operating in the global neurological biomarkersmarket are:
Neurological Biomarkers Market Strategic Developments
The key companies operating in the global neurological disorders market include Abbott Laboratories, Quanterix Corporation, Thermo Fisher Scientific Inc., Qiagen, Bio-Rad Laboratories Inc., Merck KGaA, Banyan Biomarkers Inc., Johnson & Johnson, ACOBIOM, Myriad Genetics Inc., DiaGenic ASA, and Olink Biosciences among others.
The global neurological biomarkers market is expected to grow at a revenue CAGR of 11.9% during the forecast period from 2024 to 2032.
The estimated size of the global neurological biomarkers market in 2032 is US$ 22.37 billion.
The rising prevalence rate of neurological disorders is the major driving factor in global neurological biomarkers. Additionally, the development of minimally invasive testing procedures using advanced technology is another driving factor of the global neurological market revenue growth.
North America accounts for the largest market revenue share. Asia can be considered as the key growth region due to the rapid market developments and fastest growth rate.
*Insights on financial performance are subject to the availability of information in the public domain
List of Tables
List of Figures